Introduction Atorvastatin, a potent HMG-CoA reductase inhibitor, has been widely used for lowering low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidaemia and established coronary heart disease (CHD) (1). While moderate-intensity statin therapy is well established in secondary prevention, the incremental benefit of intensive st
738 Reached
Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Complicated case of Osteoarthritis
1850 Reached2 Comments3 Likes